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Abstract: Biostatistics plays a key role in all phases of clinical research
starting from the design to the monitoring, data collection, data analysis,
and interpretation of the results. A clear understanding of the statistical
framework as it relates to the study hypothesis, reported results, and
interpretation is vital for the scientific integrity of the study and its
acceptance in the general medical community. In this brief report, we
will put in perspective the general analytical framework for exploring
and validating prognostic factors using data from large databases.
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(J Thorac Oncol. 2009;4: 1447–1449)
Biostatistics refers to the application of statistical tech-niques to biologic data collected prospectively and/or
retrospectively. Briefly, statistics plays a key role in all
phases of a research project starting from the design stage and
continuing through the monitoring, data collection, data anal-
ysis, and interpretation of the results in clinical terms. A clear
understanding of the statistical approach as it relates to the
study hypothesis, reported results, and interpretation is vital
for the scientific integrity and interpretation of the study
findings in the medical community. The important role that
statistics plays in the field of medical research and the
common statistical reporting errors and ways to avoid those
errors are well recognized and widely published.1–3
In this brief report, we will put in perspective the statistical
approach used to identify, explore, and validate prognostic
factors using data from large databases using the Chansky et al.4
article as a reference. The authors applied a systematic approach
to explore (and validate) several prognostic factors for overall
survival in a surgically managed group of patients with non-
small cell lung cancer (SCLC) using data from the large inter-
national staging database of the International Association for the
Study of Lung Cancer.4 A similar data analytic approach was
used by Foster et al.5 and Albain et al.6 to identify prognostic
factors and prognostic subgroups in SCLC, and advanced non-
SCLC, respectively. Figure 1 illustrates a general outline of the
descriptive and analytical steps involved in the data analysis
process. We discuss the salient features of each step in this
report.
DATA GATHERING AND DESCRIPTIVE
SUMMARIES
The first step in a database analysis is the selection
criteria used to determine the cases (i.e., data elements) to be
included in the analysis to ensure that (1) there is minimal to
no selection bias and (2) results arising from the analysis of
this data is reproducible, i.e., the selection criteria is not ad
hoc. Although the selection of cases is largely driven by the
scientific question at hand, it also depends on the subject
population, the variables to be explored, adequacy of avail-
able follow-up information for the end points, and attributes
of the missing data values (i.e., missing by design and
missing at random). Different approaches to handle missing
data information can be found in the statistical literature.7 The
article by Chansky et al.4 succinctly outlines the strategy they
used to arrive at their analysis sample, both overall and the
different subgroups (dependent on the missing information
for certain covariates). This is a critical step in evaluating the
scientific merit of the research study.
Once the analysis data set is identified and set up, the
next step is to explore and describe more thoroughly the end
points and the explanatory (or independent or prognostic)
variables. The outcome (i.e., end point) variables typically
fall into one of the three classes:
1. Categorical that is further classified into (a) binary or
two categories (for example, limited versus extensive
stage disease and male versus female), (b) nominal or
multiple categories with no specific order (for example,
blood group type: A, B, O, and AB), and (c) ordinal or
multiple ordered categories (for example, performance
status [PS]: 0 versus 1 versus 2; Likert type scales:
strongly agree, agree, neutral, and disagree).
2. Continuous (for example, age and white blood cell
counts).
3. Time-to-event (for example, overall survival and time
to any recurrence).
The definition of the end point, percentage of data com-
pleteness, and adequacy of follow-up information are all critical
elements that help assess the accuracy and interpretability of the
results as it relates to the end point. For example, in the case of
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time to event end points, the following issues need careful
attention: (1) the starting (date of diagnosis and date of random-
ization) and the ending time point (date of death, date of
recurrence, and date of last follow-up) used for defining the
specific end point, (2) information regarding the uniformity (and
length) of follow-up (for example, all patients are followed for a
minimum of 2 years), (3) the loss to follow-up/dropout rates
(censors) and the event rate for assessing data completeness and
determination of the number of covariates that can be explored,
and (4) the presence of competing risks (for example, both death
and distant recurrence are competing events when the event of
interest is local recurrence) and/or recurrent events (for example,
recurrent heart attacks in a coronary heart disease study).
For the explanatory variables, running simple descrip-
tive and graphical summaries to identify obvious deviations
such as outliers, sparse data within certain groups, and/or
questionable data points is usually recommended. At this
time, decisions regarding collapsing categories and/or cate-
gorization of continuous covariates are explored, which are
typically based on (1) distribution of the data, (2) underlying
biologic or clinical rationale, and (3) ease of interpretation.
However, the rationale and impact of categorizing a contin-
uous covariate on the model estimates are often not ade-
quately explored, explained, or reported in an article. Several
data-driven (such as mean and median) and outcome-oriented
techniques (such as the minimum p value approach and
twofold cross-validation) to identify optimal cutpoint(s) for
categorizing a continuous covariate are published in the
literature.8–10 The pitfalls associated with categorizing a con-
tinuous covariate, especially the potential loss of information
and incorrect assumption of the distribution of the data post
categorization are well documented in the literature.11,12 The
most commonly used approach for categorizing a continuous
covariate is a data-driven approach backed by a sound clinical
rationale as done in the article by Chansky et al.4 for the
categorization of age. The authors also discuss the impact
(which was minimal) of this categorization on the model
assumptions and the estimates.
UNIVARIABLE VERSUS MULTIVARIABLE
ANALYSIS
The next and the most critical step is the analytical
aspect that helps to draw conclusions from the data. The
general analytical approach typically includes the following
four elements:
1. Definition of the training and validation data sets, if
applicable.
2. Detailed description of all statistical procedures used to
address the research questions, including the testing and
model building framework.
3. Clearly describing the pathway from univariable to
multivariable analyses.
4. Setting threshold for declaring statistical/clinical signif-
icance a priori for the main effects, interactions. and
subgroup analyses keeping in mind the multiple com-
parisons issue.13
The use of a training data set (i.e., developmental data
set) and the validation (i.e., test data set) data set is critical to
the discovery and validation process to gauge the predictive
accuracy and performance of the original analysis in prac-
tice.14 Two common approaches include (1) cross-validation
methods, which refer to repeated partitioning of one large
data set into training and test sets and (2) use of two
independent data sets (with similar data attributes), one used
only for development and another used exclusively for vali-
dation.14 Chansky et al.4 have used the latter approach in their
article, where they developed the prognostic subgroups using
the International Association for the Study of Lung Cancer
database and validated it on the Surveillance Epidemiology
and End Results database. Using the same “data” to both
develop and validate the findings from an analysis is funda-
mentally flawed as it provides no protection against false-
positive findings due to testing the hypotheses that are orig-
inally suggested by the data itself.
The statistical techniques used to analyze the data are
closely tied to the nature of the data and the research hypoth-
esis. A univariable analysis helps to assess the strength of
association of the explanatory variable on the outcome of
interest by itself, independent of other variables. This helps to
gauge the ability of the covariate to influence outcome on its
own. In an article by Chansky et al.,4 the authors used the
Kaplan-Meier method and Cox proportional hazards regres-
sion models for the univariable analyses. It is well understood
in the statistical and clinical literature that in reality the
impact (effect size and significance) of an explanatory vari-
able on outcome when explored by itself is susceptible to
FIGURE 1. General data analysis framework.
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change when explored in the presence of other explanatory
variables. For example, Foster et al.5 report the effect of PS
on overall survival in univariable and multivariable analyses
in limited stage SCLC. In this example, although PS was not
a significant predictor of overall survival in the univariable
analysis, it was borderline significant when explored in a
multivariable setting adjusting for other covariates. Thus, it is
important to assess the possible independent effect of a
covariate on outcome in a multivariable model.
The trajectory for moving from a univariable to a
multivariable model can follow numerous paths, some of
which include the following: explore only those that are
statistically and/or clinically significant in a univariable anal-
ysis14; include all previously known important covariates as
the base model and then build a full model adding new
covariates in a step-wise fashion5; explore all covariates
explored in the univariable analysis in a multivariable anal-
ysis regardless of their significance in the univariable setting4;
or build a multivariable model using the pool of all covariates
through a selection technique (forward selection, backward
elimination, or step-wise selection).6 The statistical signifi-
cance for these analyses is usually determined by the number
of models and factors explored, the sample size/number of
events, and the clinical relevance.
A multivariable model also includes the exploration of
two-way interaction effects to assess whether the effect of a
variable on outcome differs depending on the level of another
variable. Specifically, two variables are said to interact if a
particular combination of the variables leads to results that
would not be anticipated on the basis of the main effects of
those variables. For example, Foster et al.5 describe an
interaction effect between PS and gender for patients with
extensive stage SCLC, where the effect of PS on survival
outcomes differed by gender. Although there was no impact
of PS on outcomes among women, patients with PS 0 had the
most favorable prognosis, followed by PS 1 and then PS 2
patients among men. Similarly, a small but statistically sig-
nificant interaction effect between gender and histology was
reported by Chansky et al.4
In addition to the multivariable Cox proportional hazard
regression method for assessing independent covariate effects
and interaction effects, a recursive partitioning and amalgam-
ation (RPA) analyses can be used to generate tree-based models
to identify prognostic subgroups with similar survival out-
comes.4–6,15 The RPA analysis uses the log-rank tests to deter-
mine the best splits of the data at each point to form the terminal
groupings of the tree and a bootstrap resampling approach (to
account for overfitting and adaptive nature of the algorithm) to
find the optimal sub tree.15 Unlike the multivariate Cox models
that use only complete data on all variables explored, RPA uses
all data on any individual covariate while determining the splits.
Moreover, the ability to identify prognostic subgroups and
explore interactions between covariates using RPA is relatively
straightforward (as that is the primary intent of an RPA analysis)
unlike Cox models where the final model estimates have to be
used in a regression equation (that can be quite complex) to
come up with prognostic subgroups. Although the RPA analysis
can be used to confirm the results from a Cox model (in terms
of the variables that are significant), it is more often used to
supplement the Cox models to readily and easily identify prog-
nostic subgroups.
DISCUSSION
Statistical analysis refers to a collection of methods
used to process large amounts of data and report overall
trends. It includes the collection, examination, summariza-
tion, manipulation, and interpretation of quantitative data to
discover its underlying causes, patterns, relationships, and
trends. A clear understanding of the aims of the research
project and the research data is the key to using the right
statistical tools, which in turn is essential for the accurate
interpretation of the results. In this report, we provide a
general outline of both the descriptive and the analytical
framework of statistics using real examples to illustrate how,
when, and what these analyses mean in clinical terms. This is
essential for the scientific integrity of the research study and
its acceptance in the general medical community.
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